Answers are grounded in this paper and cite their sources.
This paper reviews clinical trials with physostigmine administered to Alzheimer patients using three different routes of administration: oral, i.v. and intracerebroventricular (i.c.v.). It compares results obtained with three different routes by the authors as well as by other authors. Particular emphasis is given to a novel type of physostigmine administration, the i.c.v. route. Advantages and disadvantages, as well as side effects of each route are presented and discussed.
No takes yet. Share an insight, caveat, or question.
Becker et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: